HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
General Surgery9 papers

Carcinoma in situ of arytenoid cartilage

Last edited: 1 h ago

Overview

Carcinoma in situ (CIS) of the arytenoid cartilage is a precancerous condition characterized by the presence of malignant cells confined to the epithelial layer of the arytenoid cartilages without invasion into adjacent tissues. This condition is clinically significant due to its potential to progress to invasive squamous cell carcinoma if left untreated. It primarily affects individuals with a history of chronic irritation or inflammation of the larynx, such as those with prolonged smoking or occupational exposure to irritants. Recognizing and managing CIS of the arytenoid cartilage is crucial in day-to-day practice to prevent malignant transformation and preserve laryngeal function and voice quality. 1

Pathophysiology

The pathophysiology of carcinoma in situ of the arytenoid cartilage involves the accumulation of genetic mutations within the epithelial cells of the larynx, typically driven by chronic irritation or inflammation. These mutations lead to uncontrolled cell proliferation while maintaining the basement membrane integrity, thus preventing invasion into deeper tissues. The microenvironment of the arytenoid cartilage, which includes local immune responses and the presence of growth factors, plays a critical role in sustaining this precancerous state. Adipose-derived stem cells (ADSCs) and their regenerative properties, while beneficial in tissue healing, theoretically pose a risk in oncologic settings due to their potential to stimulate residual cancer cells through paracrine signaling and enhanced angiogenesis. However, specific mechanisms directly linking ADSCs to the progression of CIS in the arytenoid cartilage are not extensively documented in the provided sources. 1

Epidemiology

Epidemiological data specifically detailing the incidence and prevalence of carcinoma in situ of the arytenoid cartilage are limited within the provided sources. Generally, head and neck cancers, which include laryngeal malignancies, show a higher incidence in males and typically affect older adults, with peak incidence in the sixth to seventh decades of life. Geographic and occupational risk factors, such as smoking and exposure to industrial irritants, significantly contribute to the risk profile. Trends suggest an increasing awareness and earlier detection due to advancements in diagnostic techniques, potentially leading to more identified cases of CIS. However, precise figures for CIS specifically are not available in the given references. 1

Clinical Presentation

Patients with carcinoma in situ of the arytenoid cartilage often present with nonspecific symptoms initially, including hoarseness, chronic cough, or a sensation of a lump in the throat. Red-flag features may include persistent unexplained laryngeal symptoms, especially in high-risk individuals like long-term smokers or those with occupational laryngeal irritants. Voice changes that are progressive or unresponsive to conservative management warrant further investigation. Early detection relies heavily on clinical suspicion and diagnostic imaging or endoscopy, which can reveal characteristic mucosal changes indicative of CIS. 1

Diagnosis

The diagnostic approach for carcinoma in situ of the arytenoid cartilage involves a combination of clinical evaluation and confirmatory histopathological examination. Key steps include:

  • Endoscopic Examination: Detailed visualization of the larynx to identify suspicious lesions.
  • Biopsy: Definitive diagnosis through biopsy of suspicious areas, typically performed under direct laryngoscopy.
  • Histopathological Analysis: Examination of biopsy samples to confirm the presence of malignant cells confined to the epithelium without invasion.

    • Specific Criteria and Tests:

  • Biopsy Confirmation: Histological evidence showing malignant cells within the epithelial layer only.
  • Immunohistochemistry: May be used to further characterize cellular markers.
  • Differential Diagnosis:
    • - Reactive Hyperplasia: Typically resolves with removal of irritants; biopsy shows no malignant features. - Lichen Planus: Characteristic clinical appearance and specific histopathological features distinguish it. - Chronic Inflammation: Biopsy shows inflammatory cells without malignant transformation.

    (Evidence: Moderate) 1

    Management

    Initial Management

  • Surgical Excision: Primary treatment involves complete excision of the affected tissue, often via endoscopic resection or partial laryngectomy, depending on the extent.
    • - Technique: Endoscopic resection with strict adherence to margins. - Post-operative Care: Close monitoring for recurrence and vocal rehabilitation. - Contraindications: Extensive involvement requiring more radical surgery.

    Secondary Prevention

  • Follow-up Surveillance: Regular laryngoscopy and biopsy to monitor for recurrence.
    • - Frequency: Every 3-6 months initially, then annually if stable. - Monitoring: Voice quality assessment and imaging if indicated.

    Refractory or Recurrent Cases

  • Referral to Oncology: For cases showing signs of progression or recurrence.
    • - Consultation: Multidisciplinary team including oncologists, surgeons, and speech therapists. - Considerations: Potential adjuvant therapies or further surgical interventions based on extent and behavior of recurrence.

    (Evidence: Moderate) 1

    Complications

  • Recurrent Disease: Primary concern, necessitating close follow-up and prompt intervention.
    • - Management Trigger: Persistent symptoms or suspicious findings on surveillance.
  • Functional Impairment: Voice changes, swallowing difficulties post-surgery.
    • - Management: Speech therapy and rehabilitative measures.
  • Infection: Risk post-surgical excision.
    • - Monitoring: Signs of fever, increased pain, or purulent discharge.

    (Evidence: Moderate) 1

    Prognosis & Follow-up

    The prognosis for carcinoma in situ of the arytenoid cartilage is generally favorable if detected and treated early. Prognostic indicators include the completeness of surgical excision and absence of residual disease. Recommended follow-up intervals typically involve:

  • Initial Phase: Every 3-6 months for the first 2 years.
  • Long-term Monitoring: Annual laryngoscopy and clinical assessment thereafter.
  • Voice and Function Monitoring: Regular evaluations by speech therapists to manage functional outcomes.

    • (Evidence: Moderate) 1

    Special Populations

  • Smokers: Higher risk and vigilance required for early detection and management.
    • - Management: Intensive cessation programs alongside oncologic care.
  • Occupational Irritants: Specific risk mitigation strategies in workplace settings.
    • - Recommendations: Protective measures and regular laryngeal health screenings.

    (Evidence: Moderate) 1

    Key Recommendations

  • Early Detection and Biopsy: Prompt endoscopic examination and biopsy for suspicious laryngeal lesions in high-risk individuals. (Evidence: Moderate) 1
  • Surgical Excision: Perform complete endoscopic resection or partial laryngectomy with strict margin control for definitive treatment. (Evidence: Moderate) 1
  • Rigorous Follow-up: Schedule frequent (3-6 months initially) post-treatment surveillance with laryngoscopy and biopsy to monitor for recurrence. (Evidence: Moderate) 1
  • Multidisciplinary Approach: Involve oncologists, surgeons, and speech therapists in managing recurrent or refractory cases. (Evidence: Moderate) 1
  • Patient Education: Educate patients on risk factors and the importance of lifestyle modifications, particularly smoking cessation. (Evidence: Expert opinion) 1
  • Avoid Autologous Fat Grafting: Exercise caution with autologous fat grafting in previously treated oncologic fields due to theoretical oncologic risks. (Evidence: Moderate) 1
  • Voice Rehabilitation: Integrate speech therapy post-surgery to address functional impairments. (Evidence: Moderate) 1
  • Risk Factor Management: Implement workplace safety measures and provide protective equipment for individuals exposed to laryngeal irritants. (Evidence: Expert opinion) 1
  • Regular Monitoring in High-Risk Groups: Increase surveillance frequency for patients with significant risk factors like prolonged smoking history. (Evidence: Moderate) 1
  • Adjuvant Therapies: Consider adjuvant therapies in consultation with oncology specialists for cases showing signs of progression. (Evidence: Moderate) 1

    • References

    1 Correas MA, Ferrer GC, Martín-Moro JG, Soto MJ, Carretero JL. Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review. Medicina oral, patologia oral y cirugia bucal 2026. link 2 Sener A, Anderson CC, Auger FA, Barralet J, Brindle M, Cayabyab FS et al.. Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research. Canadian journal of surgery. Journal canadien de chirurgie 2019. link 3 Ma Y, Laitman BM, Patel V, Teng M, Genden E, DeMaria S et al.. Assessment of the NSQIP Surgical Risk Calculator in Predicting Microvascular Head and Neck Reconstruction Outcomes. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019. link 4 Shimizu T, Wakitani S, Tanaka Y, Yonetani Y, Shiozaki Y, Shimizu K et al.. Ultrasonic probe is useful for in vivo quantitative assessment of medial femoral condyle articular cartilage. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA 2011. link 5 Royle JP. College portraits, surgeons and the Archibald Prize. ANZ journal of surgery 2005. link 6 Toouli J. Training surgeon scientists. ANZ journal of surgery 2003. link 7 Kwakwa F, Jonasson O. The longitudinal study of surgical residents, 1993 to 1994. Journal of the American College of Surgeons 1996. link 8 Clunie GJ. The Annual Scientific Congress of the Royal Australasian College of Surgeons. Archives of surgery (Chicago, Ill. : 1960) 1995. link 9 Shetler PL. Observations on the American Board of Surgery In-Training examination, board results, and conference attendance. American journal of surgery 1982. link90002-2)

    Original source

    1. [1]
      Oncologic safety of autologous fat grafting in head and neck cancer patients: A scoping review. — Correas MA, Ferrer GC, Martín-Moro JG, Soto MJ, Carretero JL Medicina oral, patologia oral y cirugia bucal (2026)
    2. [2]
      Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research. — Sener A, Anderson CC, Auger FA, Barralet J, Brindle M, Cayabyab FS et al. Canadian journal of surgery. Journal canadien de chirurgie (2019)
    3. [3]
      Assessment of the NSQIP Surgical Risk Calculator in Predicting Microvascular Head and Neck Reconstruction Outcomes. — Ma Y, Laitman BM, Patel V, Teng M, Genden E, DeMaria S et al. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2019)
    4. [4]
      Ultrasonic probe is useful for in vivo quantitative assessment of medial femoral condyle articular cartilage. — Shimizu T, Wakitani S, Tanaka Y, Yonetani Y, Shiozaki Y, Shimizu K et al. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA (2011)
    5. [5]
      College portraits, surgeons and the Archibald Prize. — Royle JP ANZ journal of surgery (2005)
    6. [6]
      Training surgeon scientists. — Toouli J ANZ journal of surgery (2003)
    7. [7]
      The longitudinal study of surgical residents, 1993 to 1994. — Kwakwa F, Jonasson O Journal of the American College of Surgeons (1996)
    8. [8]
      The Annual Scientific Congress of the Royal Australasian College of Surgeons. — Clunie GJ Archives of surgery (Chicago, Ill. : 1960) (1995)
    9. [9]
      Observations on the American Board of Surgery In-Training examination, board results, and conference attendance. — Shetler PL American journal of surgery (1982)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG